HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy. It offers human blood cellular components derived from peripheral blood, bone marrow, and cord blood; and a range of consulting services in standard operating procedure development, personnel training, and quality and regulatory compliance. The company's network of FDA-registered, GMP/GTP-compliant collection centers ensures donor materials available to customers, as well as for use within its isolation laboratory. The company has strategic partnership with Charles River Laboratories International Inc. for human immune system research. HemaCare Corporation was founded in 1978 and is headquartered in Northridge, California.
Industry, Sector and Symbol
Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Phone818-226-1968
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
HemaCare (OTCMKTS:HEMA) Frequently Asked Questions
What is HemaCare's stock symbol?
HemaCare trades on the OTCMKTS under the ticker symbol "HEMA."
What is the consensus analysts' recommendation for HemaCare?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HemaCare in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for HemaCare.
Has HemaCare been receiving favorable news coverage?
Media stories about HEMA stock have been trending positive on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. HemaCare earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for HemaCare.
Who are some of HemaCare's key competitors?
What other stocks do shareholders of HemaCare own?
Who are HemaCare's key executives?
HemaCare's management team includes the folowing people:
- Mr. Peter C. van der Wal, Pres, CEO & Director (Age 62)
- Ms. Rochelle J. Martel M.B.A., CPA, Chief Financial Officer
- Ms. Maria Pia Muniz, Sr. VP of Operations
- Mr. Lou Juliano, Sr. VP of Global Sales & Bus. Devel.
- Dr. Dominic Clarke, Global Head of Cell Therapy
How do I buy shares of HemaCare?
Shares of HEMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is HemaCare's stock price today?
One share of HEMA stock can currently be purchased for approximately $13.90.
How big of a company is HemaCare?
What is HemaCare's official website?
How can I contact HemaCare?
HemaCare's mailing address is 15350 SHERMAN WAY SUITE 350, VAN NUYS CA, 91406. The company can be reached via phone at 818-226-1968 or via email at [email protected]
MarketBeat Community Rating for HemaCare (OTCMKTS HEMA)
MarketBeat's community ratings are surveys of what our community members think about HemaCare and other stocks. Vote "Outperform" if you believe HEMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
